

KM Surgical Ltd



DERMATOLOGY ASSOCIATES LTD

**Dr Ken Macdonald**

**Dermatologist ,  
Dermatologic Surgeon**

## DIAGNOSTIC PLANNER

### Factors to consider when formulating a differential diagnosis

Symptoms (eg fever, pain, pruritis)

Duration and temporal pattern (acute, sub-acute, chronic, intermittent)

Primary lesions: macules, patches, papules, pustules, nodules, plaques, vesicles, bullae

Secondary morphology: scale, crust, erosions, ulcers, scars, purpura, pallor, cyanosis

Arrangement: annular, linear, solitary, generalised,

Anatomical location: palmar plantar, acral, truncal etc

Colour: black, blue, brown, red, flesh-coloured, cream, xanthotic

Laboratory findings

Histopathologic findings

### Is the skin condition/lesion

Epidermal, dermal, subcutaneous or mixed level?

Inflammatory (infectious/non infectious) or papulo-squamous?

Neoplastic (benign or malignant)?

Solitary or multiple lesions/characteristic distribution?

### Is there

Any past personal, family or contact history?

Any relevant medication/drug/occupational history?

Any injury/self harm?

























Dysplastic nevus



BCC




Compound nevus



Melanoma  
in situ



Blue nevus



MM



# Dermoscopy

## 3 point check list

- asymmetry
- atypical network
- blue white structures

## 5 melanoma specific local criteria

- atypical network
- irregular streaks
- irregular dots/globules
- irregular blotches
- blue white structures

## 6 criteria for non melanocytic lesions

- blue gray blotches
- arborizing vessels
- milia like cysts
- comedo like openings
- red blue lacunae
- central white patch











## FACIAL PIGMENTATION

- Depth (epidermal or dermal)
- Type (melanocytic or not)
- Skin type
- Ethnic background

### Drugs:

Minocycline  
Clofazimine  
Amioderone  
Zidovudine (AZT) – blue lunulae  
Diltiazem (Skin types IV or V)  
Dioxins  
Hydroquinone (ochronosis)  
Psychotropic drugs  
Psoralens  
Hormones  
Chemotherapeutic agents – B, C, D, F, H, MTX  
Antimalarials  
Heavy metals – arsenic, gold, iron, silver, lead, mercury

## MELASMA/CHLOASMA – HYPERPIGMENTATION

- Erythema dyschromicum perstans (Ashy dermatitis)
- Lichen planus pigmentosum (actinic)
- Primary cutaneous amyloidosis
- Cafe au lait pigmentation
- Haemosiderin
- Nevus of Ota
- Pot traumatic
- Post inflammatory (numerous causes)
- Poikiloderma of Civatte
- Phytotoxic and phytophototoxicity

# Skin Cancer – Pigmented Lesions Differential Diagnosis

- Tattoos – Foreign bodies – calciphylaxis
- Argyria – minocycline dyspigmentation (other drugs)
- Angiokeratoma – angiosarcoma – venous lake
- Open comedone – cyst – blue naevus – hidrocystoma
- Post inflammatory – pigmented purpuric dermatoses (haemosiderin)
- Lichen planus – naevus of Ota – ochronosis
- Talon noir – Terra firma dermatosis – dermatosis papulosa nigra
- Lentigo simplex – stellate lentigo – solar lentigo – chloasma
- Warfarin necrosis – purpura – gangrene – sub unguis haemorrhage
- Seborrheic lentigo – pigmented actinic keratosis – Bowen's disease
- Many other dermatoses esp. Pigmented skin types
- Deep dermal blue/black discolouration from any particulate matter.





















## Tender/Painful Nodules

### Not inflamed

- E**      Eccrine spiradenoma/erythematous nodosum
- N**      Neurilemmoma
- G**      Glomus tumour
- L**      Leiomyoma
- A**      Angiolipoma/arthropod sting
- N**      Neuroma/neurofibroma
- D**      Dercum's/dermatofibroma

### Inflamed

- Keratoacanthoma
- Acne nodules/hydradenitis
- Epidermal cyst (inflamed)
- Staph lesions (boils, furuncles)
- Vasculitis/paniculitis
- Sweets neutrophilic dermatosis
- Chondrodermatitis helioides









# ACNE

- Multifactorial disorder of pilosebaceous units
- Significant psychologic and economic impacts
- Comedones, papules, pustules, cysts, scarring

## Increased risk -

- xxy genotype
- PCOD
- hypercortisolism
- precocious puberty

## Pathogenesis

- genetic predisposition (sebaceous glands)
- hormonal responsiveness – sebum excretion
- increased cellular cohesion and proliferation
- comedone formation and rupture
- propionibacterium acnes (coproporphyrin III)
- immune response
- DHEA → testosterone → DHT

## Clinical

- non-inflammatory (comedones, open and closed, micro and macro) scars; ice pick erythematous papules; sterile pustules indurated nodules and cysts scars, hypertrophic, atrophic depressed, aggregated pitted, bridged, tethered

## Acne Variants

- acne fulminans (haemorrhagic plaques, fever, osteolytic lesions)
- acne conglobata (eruptive nodulo-cystic acne)
- solid facial oedema
- acne mechanica
- acne excoriée des jeunes filles
- drug induced acne (steroids, azathioprine, PUVA etc)
- occupational acne (follicular occlusion tetrad)
- chloracne (halogenated hydrocarbons)
- EGFR inhibitors
- neonatal and infantile
- radiation
- endocrine
- tropical

## Isotretinoin (13-cis-retinoic acid) since 1971

- Severe inflammatory nodulo-cystic acne
- Persistent inflammatory acne with scarring potential
- Other inflammatory acne resulting in significant emotional stress (dysmorphophobia)

Isotretinoin induced (1) sebaceous gland atrophy by prohibiting maturation of basal cells (2) normalisation of follicular keratinisation (3) reduction of p. acnes.

Dosing varies (0.5 – 1.0mg/kg/day for 16-20 weeks). Lower dose regimens may be equally effective. Repeat treatments in 40% of patients. Intermittent and long term treatments experimental.

### Lab studies on all patients:

complete blood count  
Liver function  
Creatinine  
Fasting lipids  
HCG

### Poor responders

Repeat lab studies  
macrocomedones  
dry skin types  
persistent inflammation females  
scarred nodules and sinus tracts  
endocrine disorders

### Combined treatment

prednisone  
erythromycin (tetracyclines contraindicated)

## Side effects

- numerous (retinoic acid receptors ubiquitous)
- skin and mucous membranes (dose related) dryness, cheilitis
- alopecia, facial hair, dermatitis may occur
- xerophthalmia, conjunctivitis
- photophobia, night vision impairment, keratitis
- neuromuscular – myalgia, headache, fatigue, blurred vision
- superinfection (impetigo)
- GI irritation, nausea, vomiting, anorexia
- hepatitis rare and reversible
- benign intracranial hypertension (tetracyclines)
- psychiatric effects – suicide, suicidal ideation, depression ?a ‘real’ phenomenon but NB careful monitoring and support systems in place probable idiosyncratic and unrelated to previous or family history
- central effects – tiredness, lethargy, anxiety
- skeletal effects

### Issue of teratogenicity

- individualise each situation
- menstrual cycle may be disrupted

### Issue of consenting

- written consent
- initial against each point
- sign and witness

### Other medication

- OCP, antidepressants, antibiotics

## PHYSICAL TREATMENTS

- comedo extraction/peels (TCA, glycolic acid)
- electrosurgery/curettage
- blue light acne therapy
- photodynamic therapy
- near infrared lasers
- subcision/excision/punch grafting
- dermabrasion/laser resurfacing
- deep fractional CO<sup>2</sup> laser resurfacing
- soft tissue augmentation/fat transfer














- Common, disfiguring, male and female, fair skinned, 3<sup>rd</sup> and 4<sup>th</sup> decade

- **Pathogenesis multifactorial**
  - vascular hyper reactivity – vasodilation
  - Neuro cutaneous component – bacterial overgrowth – dermatex
  - Corticosteroid association – U.V. exposure – ‘sensitive skin’

- **Variants** – granulomatous/periorificial/steroid/pyoderma faciale/lymphoedema/lupus miliaris disseminatus

- **1° features:**
  - flushing (transient erythema)
  - non-transient erythema
  - papules and pustules
  - telangiectasia

- **2° features:**
  - burning/stinging ensation central face
  - pustular plaques/confluence of papules
  - dryness and flaking of central facial skin
  - soft or solid facial/forehead oedema
  - ocular/rhinophyma/extra facial

- **Differential diagnosis**
  - seborrhoeic dermatitis, acne vulgaris
  - erythromelanosia, keratosis pilaris rubra
  - lupus erythematosus
  - Haber syndrome – demodex folliculitis (HIV)

## ROSACEA TREATMENT

### **Topical**

- metronidazole cream or gel (0.75%)
- Sulphur and salicylic acid (<2%)
- Azelaic acid (15% - 20%)
- Benzoyl peroxide 5%, clindamycin 1% (DUAC)
- Tretinoin <0.1% cream or gel
- Vitamin C

### **Oral**

- Tetracyclines
- Erythromycins
- Cotrimoxazole
- Isotretinoin

### **Physical**


- Intense Pulsed Light
- KTP (532nm) laser
- Pulsed dye laser
- CO<sup>2</sup> laser
- Surgical
- electrosurgical



# FOLLICULITIS


## Superficial and deep

- Disorder of follicular keratinisation
- Follicular occlusion tetrad (acne conglobata, hidradenitis suppurativa)
- Dissecting cellulitis, pilonidal sinus)



- Pustules and erythema
- Terminal hairs

|



- Eosinophilic (lymphoma, AIDS, neonatal) – pustular (Ofuji's)
- Irritant folliculitis (tars, ointments, etc)
- Gram negative folliculitis (pseudomonas, klebsiella, enterobacter, proteus spp)
  - - long term antibiotics RX/hot tub "spa" folliculitis - -)
- Dermatophyte folliculitis (T. metagrophytes/verrucosum/rubrum 'Majocchi's')
- Pityrosporum folliculitis (young adults/warm weather/occlusion/↑sebum)
- Candida folliculitis (diabetics)
- Phrynoderma (vit A deficiency)
- Herpes simplex folliculitis (males shaving, HIV positive)
- Dermadox folliculitis (immune suppression)
- Drug induced folliculitis (steroids, androgens, iodides, lithium (AGEP), cotrimoxazole)
- Actinic folliculitis (hours x sun exposure or x phototherapy)








# NON MELANOMA SKIN CANCER (NMSC)

Evaluation and risk management:



## Physical exam

- Location and size
- Palpation/tethered
- Definition

## Biopsy

- Tumour type
- Depth
- Prognosis

Neurologic symptoms

Past history

Family history

Lymphadenopathy

## Surgical Mangement (tumour size is important)

BCC invasive

4mm excision margins or Mohs

SCC (high risk)

6mm excision margins or Mohs



## RISK FACTORS FOR RECURRENCE OF NON MELANOMA SKIN CANCER


	LOW RISK	HIGH RISK
<b>CLINICAL RISK FACTORS</b>		
Location/size	Area L <20mm Area M <10mm Area H <6mm	Area L >20mm Area M >10mm Area H >6mm
Borders	Well defined	Poorly defined
Primary vs recurrent	Primary	Recurrent
Immunosuppression	Negative	Positive
Tumour at site of prior radiation therapy	Negative	Positive
Rapidly growing tumour (SCC only)	Negative	Positive
Neurologic symptoms: pain, paresthesia, paralysis (SCC only)	Negative	Positive
<b>PATHOLOGIC RISK FACTORS</b>		
Perineural involvement	Negative	Positive
Subtype (BCC only)	Nodular, superficial	Micronodular, infiltrating, sclerosing
Degree of differentiation	Well differentiated	Moderately or poorly differentiated
Adenoid, adenosquamous or desmoplastic (SCC only)	Negative	Positive
Depth: Clark level or thickness (SCC only)	I, II, III or <4mm	IV, V or >4mm

**Area L:** Low risk: trunk, extremities

**Area M:** Medium risk: cheeks, forehead, neck, scalp

**Area H:** High risk: central face, eyelids, eyebrows, periorbital, nose, lips, chin, mandible, periauricular, ears, genitalia, hands and feet















































# ATOPIC DERMATITIS

## **Major Features (3 of 4 present)**

Pruritus (polished nails/subungual debris)  
Typical morphology/distribution of skin lesions  
Chronic or chronically relapsing dermatitis  
Personal or family history of atopy

## **Minor Features**

Xerosis/asteatosis/dryness of skin  
AD ichthyosis/palmar hyperlinearity  
'Type I' skin test reactivity  
Elevated IgE/positive RAST tests  
Cheilitis/conjunctivitis/blepharitis  
Infraorbital fold/'nasal' salute  
Facial pallor/erythema  
White dermographism

# ATOPIC DERMATITIS

## Therapeutic ladder

- Emollients (maintenance and relapse prevention)
- Irritant avoidance and recognition of other trigger factors
- Treatment of associated bacterial, viral or fungal infections
- Oral antihistamines for antipruritic and sedative effects
- Topical corticosteroids/intralesional corticosteroids
- Topical calcineurin inhibitors
- Other topical including coal tar derivatives
- Narrowband UVB phototherapy
- Systemic corticosteroids (short term)
- Cyclosporine
- Azathioprine
- Methotrexate/mycophenolate
- Interferon/ intravenous immunoglobulin
- Biologic agents (efalizumab, infliximab, omalizumab)

## **ATOPIC DERMATITIS**

Interaction between environmental and genetic factors

- Hygiene hypothesis – Auto allergy IgE x link
- Defective epidermal barrier and bacterial colonisation
- Acute stage: Th2 cells and cytokines. Chronic stage: Th1.
- Loss of function mutations in the filaggrin gene – keratin aggregation



# ATOPIC DERMATITIS

## DIFFERENTIAL DIAGNOSIS

Psoriasis/pityriasis rubrapilaris

Seborrhoeic dermatitis

Asteatotic eczema

Venous syndrome dermatitis

Nummular dermatitis

Pityriasis alba

Pityriasis rosea

Juvenile plantar dermatosis

Parapsoriasis/superficial scaly dermatitis

Impetiginised eczema

Eczema herpeticum

Dermatophytosis/eczema herpeticum

Rosaceous dermatitis (POD)

Lichen planus/lichen planopilaris

Keratosis pilaris/follicular ichthyosis

Lichen simplex chronicus

Nodular prurigo

Contact irritant/allergic dermatitis

Photosensitivity dermatitis

Chronic actinic dermatitis

Drug eruption

Graft versus host disease

Systemic lupus erythematosus

Dermatomyositis

Pemphigus foliaceus

Cutaneous T-cell lymphoma

Histiocytosis (Langerhaus cell)

Primary immune deficiencies

Metabolic and genetic disorders

HIV associated dermatosis

Scabies/cutaneous larva migrans

Sarcoid/TB/syphilis

Dermatitis artefacta